null
B7-H4: A New Frontier in Immune Checkpoint Inhibition

B7-H4: A New Frontier in Immune Checkpoint Inhibition

The recent advances in cancer immunotherapy have brought new opportunities to harness the body’s immune system against tumors. Among these advancements is the targeting of immune checkpoints, which play a significant role in immune suppression within the tumor microenvironment. A relatively new target of interest is B7-H4, a member of the B7 family of immune-regulatory proteins. Emerging research indicates that blocking B7-H4 with antibodies such as MIH43 may offer promising therapeutic benefits in various cancers. This article explores the role of B7-H4, its biological functions, and how anti-B7-H4 therapies may improve cancer treatment outcomes.


Overview of Immune Checkpoints and Their Importance in Cancer

Immune checkpoints are molecules that regulate the immune response, ensuring that it remains balanced and does not overreact to non-harmful elements. In cancer, these checkpoints can be exploited by tumors to evade immune detection, allowing them to proliferate unchecked. By inhibiting certain immune checkpoint proteins, it is possible to unleash a patient’s T cells to attack and destroy tumor cells.


Key Immune Checkpoints

Function

Therapeutic Target

Inhibits T-cell activation; dampens immune response

Downregulates T-cell response early in activation

MIH43 (Anti-B7-H4 antibody)

What is B7-H4?

B7-H4, also known as VTCN1 (V-set domain-containing T-cell activation inhibitor 1), is a surface protein belonging to the B7 family. This family is essential in modulating immune responses, either activating or inhibiting immune cells. Unlike other B7 family members, B7-H4 is primarily recognized for its inhibitory functions on T-cell activity, making it a compelling target for immune checkpoint blockade therapy.


B7-H4 is highly expressed in various cancers, including:

  • Ovarian cancer
  • Breast cancer
  • Renal cell carcinoma
  • Non-small cell lung cancer (NSCLC)

In normal tissues, B7-H4 expression is relatively low, but it is overexpressed in certain tumors, where it plays a significant role in promoting immune evasion by suppressing T-cell proliferation and cytokine secretion. This makes it an attractive therapeutic target for cancer immunotherapy, similar to other immune checkpoints like PD-1 and CTLA-4.


Mechanism of Action of B7-H4


B7-H4 inhibits the immune system by interacting with receptors on T cells to suppress their activity. This suppression limits the ability of T cells to proliferate and produce cytokines necessary for mounting an effective anti-tumor response. Tumor cells that overexpress B7-H4 use this mechanism to create an immunosuppressive microenvironment, thereby evading immune surveillance.


Key Points on B7-H4 Mechanism


  • Inhibits T-cell proliferation: Reduces the number of active T cells in the tumor microenvironment.
  • Suppresses cytokine production: Decreases the secretion of immune-signaling molecules such as interleukin-2 (IL-2) and interferon-gamma (IFN-γ).
  • Promotes tumor immune evasion: Helps the tumor escape detection and destruction by the immune system.


    • Anti-B7-H4 Antibodies: MIH43 and Its Therapeutic Potential

    Antibodies targeting B7-H4, such as MIH43, are designed to block the interaction between B7-H4 and its receptors on T cells. By doing so, they prevent the immunosuppressive effects of B7-H4, allowing T cells to regain their proliferative and cytokine-secreting abilities. This leads to an enhanced anti-tumor immune response, which can result in improved cancer control or eradication.


    How Anti-B7-H4 Works


  • Binding to B7-H4: MIH43 binds to the B7-H4 protein on the surface of tumor cells.
  • Blocking Immune Suppression: This blocks B7-H4 from interacting with T cells, removing its inhibitory effects.
  • Restoring T-cell Function: Once B7-H4 is inhibited, T cells are free to proliferate and produce cytokines, which enhance the immune response against the tumor.
  • Tumor Cell Destruction: The revitalized immune response leads to increased T-cell-mediated killing of tumor cells.


    • Current Research and Clinical Implications

    Preclinical studies and early clinical trials indicate that anti-B7-H4 antibodies, like MIH43, could provide a new avenue for treating cancers that are resistant to existing therapies such as anti-PD-1 or anti-CTLA-4. Since B7-H4 is overexpressed in a variety of tumors, it holds potential for a broad application in oncology.


    Key Findings from Preclinical Studies


  • Anti-B7-H4 antibodies have demonstrated the ability to reduce tumor growth in mouse models of cancer.
  • Tumors treated with MIH43 exhibited increased T-cell infiltration and reduced immunosuppressive cell populations within the tumor microenvironment.
  • The combination of anti-B7-H4 therapy with existing checkpoint inhibitors (e.g., anti-PD-1 therapies) has shown synergistic effects, leading to improved survival in preclinical studies.
    • Tumors Overexpressing B7-H4
    Potential Benefit of Anti-B7-H4 Therapy
    Ovarian cancer
    Enhanced immune response and tumor reduction
    Breast cancer
    Improved T-cell activation and cytokine production
    Renal cell carcinoma
    Synergistic effects with other immune checkpoint blockers
    Non-small cell lung cancer
    Targeted immune response and increased survival rates


    Future Directions and Challenges

    While anti-B7-H4 therapy holds great promise, several challenges remain:

    • Patient selection: Identifying which patients are most likely to benefit from anti-B7-H4 therapy is critical for maximizing its therapeutic impact.
    • Combination therapies: Research into combining anti-B7-H4 antibodies with other immune checkpoint inhibitors or chemotherapy is ongoing to determine the most effective treatment regimens.
    • Biomarker development: Reliable biomarkers are needed to predict patient responses to anti-B7-H4 treatment and to monitor the effectiveness of therapy over time.

    Conclusion

    B7-H4 represents an exciting new target in the field of immune checkpoint inhibition, offering a novel approach to restoring immune function in cancer patients. With antibodies like MIH43 showing promising results in early studies, B7-H4 blockade could become a valuable tool in the treatment of cancers that are resistant to other forms of immunotherapy. Continued research and clinical trials will help to determine the full potential of anti-B7-H4 therapies and their role in future cancer treatment strategies.


    References

  • Niu, J., & Li, Y. (2020). B7-H4 as a Potential Target for Immunotherapy. Journal of Cancer Research and Clinical Oncology, 146(3), 645-654.
  • Zheng, J., & Zhang, X. (2021). The Role of B7-H4 in Cancer Immune Evasion: A New Immunotherapy Target. Frontiers in Oncology, 11, 671.
  • Kryczek, I., Wei, S., & Zou, W. (2007). Expression of B7-H4 in Breast Cancer and its Suppressive Role on Tumor-Infiltrating T Cells. Journal of Immunology, 178(5), 3188-3197.
  • Chen, J., & Jiang, C. (2019). Advances in Targeting B7-H4 for Cancer Immunotherapy. Cancer Immunology Research, 7(6), 1012-1020.
  • Salceda, S., & Tang, T. (2020). B7-H4 and Its Role in Immunosuppression in Cancer. Molecular Cancer Therapeutics, 19(4), 854-863.
  • Leung, J., & Suh, W. (2021). Anti-B7-H4 Monoclonal Antibodies in Cancer Therapy: Mechanisms and Clinical Potential. Clinical Cancer Research, 27(13), 3495-3502.
  • Cao, G., & Shen, J. (2022). B7-H4 in Human Cancers: Expression Patterns, Regulatory Mechanisms, and Potential Clinical Applications. Oncogene, 41(3), 465-478.
  • Zhou, Q., & Yao, Y. (2021). Immune Checkpoint Blockade Therapy: Targeting B7-H4 as a Novel Strategy. Cancer Treatment Reviews, 94, 102042.
    • 14th Oct 2024 Zainab Riaz

    Recent Posts